DelveInsight's 'Lipodystrophy - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Lipodystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Lipodystrophy epidemiology report gives a thorough understanding of the Lipodystrophy by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Lipodystrophy in the US, Europe, and Japan. The report covers the detailed information of the Lipodystrophy epidemiology scenario in seven major countries (US, EU5, and Japan).
The Lipodystrophy epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Lipodystrophy epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Lipodystrophy epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Lipodystrophy epidemiology covered in the report provides historical as well as forecasted Lipodystrophy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Lipodystrophy report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Lipodystrophy
3. Lipodystrophy: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Lipodystrophy Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Lipodystrophy Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Lipodystrophy Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Lipodystrophy Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Lipodystrophy Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Lipodystrophy Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Lipodystrophy Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Lipodystrophy Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Lipodystrophy Treatment and Management
6.2. Lipodystrophy Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Lipodystrophy Epidemiology in 7MM (2017-2030)
Table 2 Lipodystrophy Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Lipodystrophy Epidemiology in the United States (2017-2030)
Table 4 Lipodystrophy Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Lipodystrophy Epidemiology in Germany (2017-2030)
Table 6 Lipodystrophy Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Lipodystrophy Epidemiology in France (2017-2030)
Table 8 Lipodystrophy Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Lipodystrophy Epidemiology in Italy (2017-2030)
Table 10 Lipodystrophy Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Lipodystrophy Epidemiology in Spain (2017-2030)
Table 12 Lipodystrophy Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Lipodystrophy Epidemiology in the United Kingdom (2017-2030)
Table 14 Lipodystrophy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Lipodystrophy Epidemiology in Japan (2017-2030)
Table 16 Lipodystrophy Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Lipodystrophy Epidemiology in 7MM (2017-2030)
Figure 2 Lipodystrophy Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Lipodystrophy Epidemiology in the United States (2017-2030)
Figure 4 Lipodystrophy Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Lipodystrophy Epidemiology in Germany (2017-2030)
Figure 6 Lipodystrophy Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Lipodystrophy Epidemiology in France (2017-2030)
Figure 8 Lipodystrophy Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Lipodystrophy Epidemiology in Italy (2017-2030)
Figure 10 Lipodystrophy Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Lipodystrophy Epidemiology in Spain (2017-2030)
Figure 12 Lipodystrophy Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Lipodystrophy Epidemiology in the United Kingdom (2017-2030)
Figure 14 Lipodystrophy Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Lipodystrophy Epidemiology in Japan (2017-2030)
Figure 16 Lipodystrophy Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report
